Answers are grounded in this paper and cite their sources.
To the editor—Hyperpigmentation has been described in association with the use of several medications, including quinidine [1], terbinafine [2], and the tetracyclines [3]. Minocycline hyperpigmentation has been noted to occur at various sites, including the skin [4, 5], thyroid gland [6, 7], and sclera [8]. In cases of skin hyperpigmentation, the areas of pigmentation have typically been focal in distribution [4, 5]. Tigecycline, the first of a new class of antibiotics known as glycylcyclines, is a semisynthetic derivative of minocycline. To date, there have been no published reports of hyperpigmentation attributed to tigecycline use. We describe 2 patients who developed diffuse cutaneous hyperpigmentation while receiving treatment with tigecycline. A 46-year-old Hispanic man with a myocardial infarction was admitted to the hospital for coronary artery bypass surgery. He subsequently developed pneumonia, and carbapenem-resistant Klebsiella pneumoniae was recovered from a tracheal aspirate specimen. The patient started receiving a regimen of tigecycline (50 mg intravenously every 12 h after an initial 100-mg loading dose) and polymyxin B. Two weeks after the initiation of therapy, blood cultures also became positive for K. pneumoniae, with the same resistance profile as the organisms recovered from the tracheal aspirate specimen. Subsequent blood cultures were sterile, and treatment with both tigecycline and polymyxin B was stopped after 14 days from the first sterile blood cultures (after a total of 29 days on antibiotic therapy). Just before the patient completed the course of antibiotics, the patient's family noticed significant darkening of the patient's face, ears, neck, and upper chest that progressed over the next several days. Other medications that the patient used before the onset of hyperpigmentation included metronidazole, rifampin, oral vancomycin, simvastatin, metoclopramide, amiodarone, lisinopril, metoprolol, phenytoin, clonazepam, furosemide, methylphenidate, intravenous heparin, intravenous norepinephrine, lorazepam, hydromorphone, fentanyl, esomeprazole, aspirin, and epoetin. Over the next 3 months, the patient reported a gradual decrease in skin pigmentation, although it still had not returned to its original appearance. An 80-year-old Hispanic man with a history of diabetes mellitus and end-stage renal disease was admitted to an outside hospital with fever and chills after he had undergone hemodialysis. Blood cultures revealed highly drug-resistant K. pneumoniae, and the patient initiated a regimen of polymyxin B. Seven days later, he was transferred to our hospital for additional treatment, at which time tigecycline (50 mg intravenously every 12 h after an initial 100-mg loading dose) was added to the treatment regimen. Tigecycline and polymyxin B were discontinued after 16 days from the first sterile blood cultures (after a total of 22 days of tigecycline treatment and 30 days of polymyxin B treatment). Two days after the patient stopping taking both antibiotics, he developed darkening of the skin that primarily involved his face. Other medications that the patient had used before the onset of hyperpigmentation included insulin aspart and esomeprazole. His hyperpigmentation subsequently decreased but did not completely resolve, even after 5 months of therapy. Tigecycline is a new antibiotic with activity against a variety of gram-positive, gram-negative, anaerobic, and atypical organisms, including drug-resistant, gram-negative Enterobacteriaceae, such as K. pneumoniae [9,10,11–12]. As tigecycline use becomes more prevalent, additional adverse effects are likely to be reported. Although, to our knowledge, tigecycline hyperpigmentation has not yet been reported elsewhere, significant literature exists describing various pigmentation abnormalities associated with minocycline, which is structurally similar to tigecycline. It is unclear whether the aforementioned skin changes imply that tigecycline (alone or in combination with polymyxin B) can cause these skin manifestations. Although both patients were receiving polymyxin B, it is unlikely that this agent was responsible for the skin pigmentation, given our institution's extensive use of polymyxin B without prior skin changes having being observed. of the medicines listed above that were given to our patients, it has been documented in the literature that rifampin [13, 14], amiodarone [15, 16], and phenytoin [17, 18] have caused cutaneous hyperpigmentation, although none of the documented cases had patterns similar to those seen in our patients. We cannot exclude the possibility that one of these other medications was responsible for the skin changes. However, tigecycline, polymyxin B, and esomeprazole were the only medications that were administered to both patients, and esomeprazole has not been reported to cause hyperpigmentation. Furthermore, both cases involved diffuse hyperpigmentation that predominantly affected the face, suggesting a similar etiology. We recommend that patients receiving tigecycline, either alone or in combination with polymyxin B, be monitored for hyperpigmentation. Potential conflicts of interest. R.C.K. and J.R.: no conflicts.
No takes yet. Share an insight, caveat, or question.
Knueppel et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: